STOCK TITAN

[Form 4] Barrett Business Services Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Arteris, Inc. (NASDAQ: AIP) – Form 144 filing discloses that a shareholder intends to sell up to 1,554 common shares through Morgan Stanley Smith Barney on or after 07 / 03 / 2025. The estimated aggregate market value is $14,125.86. Total shares outstanding are 41,977,728, so the proposed sale represents roughly 0.0037 % of shares outstanding.

The filer—identified in the accompanying sales history as “10b5-1 Sales Plan for Laurent Moll” and “Laurent Moll”—has already disposed of 2,368 shares over the past three months through multiple Rule 10b5-1 transactions, generating $16,743 in gross proceeds. Combined with the new notice, total contemplated and recent sales amount to 3,922 shares, or approximately 0.009 % of outstanding shares.

No information on the seller’s relationship to Arteris, the purpose of the sale, or any material, non-public information is provided, and the standard Rule 144 representation affirms the seller’s lack of undisclosed adverse knowledge. Given the de-minimis size relative to the public float, the filing is unlikely to have a material impact on AIP’s share price, but investors may note the continued insider selling trend.

Arteris, Inc. (NASDAQ: AIP) – Deposito Form 144 rivela che un azionista intende vendere fino a 1.554 azioni ordinarie tramite Morgan Stanley Smith Barney a partire dal 07/03/2025. Il valore di mercato aggregato stimato è di 14.125,86 $. Le azioni totali in circolazione sono 41.977.728, quindi la vendita proposta rappresenta circa lo 0,0037 % delle azioni in circolazione.

Il dichiarante — identificato nella cronologia delle vendite come “Piano di vendita 10b5-1 per Laurent Moll” e “Laurent Moll” — ha già ceduto 2.368 azioni negli ultimi tre mesi tramite diverse transazioni ai sensi della Regola 10b5-1, generando 16.743 $ di proventi lordi. Sommandoli alla nuova comunicazione, le vendite recenti e previste ammontano a 3.922 azioni, ovvero circa lo 0,009 % delle azioni in circolazione.

Non sono fornite informazioni sul rapporto del venditore con Arteris, sullo scopo della vendita o su eventuali informazioni materiali non pubbliche, e la dichiarazione standard della Regola 144 conferma l’assenza di conoscenze sfavorevoli non divulgate da parte del venditore. Data la dimensione minima rispetto al flottante pubblico, il deposito difficilmente influenzerà in modo significativo il prezzo delle azioni AIP, ma gli investitori potrebbero notare la continuazione della tendenza alle vendite da parte degli insider.

Arteris, Inc. (NASDAQ: AIP) – Presentación del Formulario 144 revela que un accionista planea vender hasta 1,554 acciones comunes a través de Morgan Stanley Smith Barney a partir del 07/03/2025. El valor de mercado agregado estimado es de $14,125.86. El total de acciones en circulación es de 41,977,728, por lo que la venta propuesta representa aproximadamente el 0.0037 % de las acciones en circulación.

El declarante — identificado en el historial de ventas adjunto como “Plan de ventas 10b5-1 para Laurent Moll” y “Laurent Moll” — ya ha vendido 2,368 acciones en los últimos tres meses mediante múltiples transacciones bajo la Regla 10b5-1, generando $16,743 en ingresos brutos. Sumando esta nueva notificación, las ventas recientes y contempladas ascienden a 3,922 acciones, o aproximadamente el 0.009 % de las acciones en circulación.

No se proporciona información sobre la relación del vendedor con Arteris, el propósito de la venta ni sobre información material no pública, y la representación estándar de la Regla 144 afirma la ausencia de conocimiento adverso no divulgado por parte del vendedor. Dado el tamaño insignificante en relación con el flotante público, es poco probable que la presentación tenga un impacto material en el precio de las acciones de AIP, pero los inversores pueden notar la tendencia continua de ventas internas.

Arteris, Inc. (NASDAQ: AIP) – Form 144 제출에 따르면 한 주주가 2025년 7월 3일 이후 Morgan Stanley Smith Barney를 통해 최대 1,554 보통주를 매도할 예정입니다. 추정 총 시장 가치는 $14,125.86입니다. 총 발행 주식 수는 41,977,728주로, 이번 매도는 전체 발행 주식의 약 0.0037%에 해당합니다.

신고자—첨부된 매도 내역에서 “Laurent Moll을 위한 10b5-1 매도 계획” 및 “Laurent Moll”로 식별됨—은 지난 3개월 동안 여러 10b5-1 규정에 따른 거래를 통해 이미 2,368주를 처분하여 총 $16,743의 매출을 올렸습니다. 이번 신규 공지와 합산하면 최근 및 예정된 매도는 총 3,922주로, 전체 발행 주식의 약 0.009%에 해당합니다.

판매자의 Arteris와의 관계, 매도 목적, 비공개 중요 정보에 대한 정보는 제공되지 않았으며, 표준 144규정 진술은 판매자가 미공개 불리한 정보를 보유하지 않았음을 확인합니다. 공공 유통 주식 대비 매우 작은 규모이므로 이번 제출이 AIP 주가에 미치는 영향은 크지 않을 것으로 보이나, 투자자들은 내부자 매도 추세가 계속되고 있음을 주목할 수 있습니다.

Arteris, Inc. (NASDAQ : AIP) – Dépôt du formulaire 144 révèle qu'un actionnaire prévoit de vendre jusqu'à 1 554 actions ordinaires via Morgan Stanley Smith Barney à compter du 03/07/2025. La valeur marchande agrégée estimée est de 14 125,86 $. Le nombre total d'actions en circulation est de 41 977 728, de sorte que la vente proposée représente environ 0,0037 % des actions en circulation.

Le déclarant — identifié dans l'historique des ventes joint comme « Plan de vente 10b5-1 pour Laurent Moll » et « Laurent Moll » — a déjà cédé 2 368 actions au cours des trois derniers mois via plusieurs transactions conformément à la règle 10b5-1, générant 16 743 $ de produit brut. En combinant avec cette nouvelle notification, les ventes récentes et envisagées s'élèvent à 3 922 actions, soit environ 0,009 % des actions en circulation.

Aucune information sur la relation du vendeur avec Arteris, l'objet de la vente ou toute information matérielle non publique n'est fournie, et la déclaration standard de la règle 144 confirme l'absence de connaissance défavorable non divulguée par le vendeur. Étant donné la taille négligeable par rapport au flottant public, ce dépôt est peu susceptible d'avoir un impact significatif sur le cours de l'action AIP, mais les investisseurs peuvent noter la poursuite de la tendance des ventes d'initiés.

Arteris, Inc. (NASDAQ: AIP) – Form 144 Einreichung zeigt, dass ein Aktionär beabsichtigt, bis zu 1.554 Stammaktien über Morgan Stanley Smith Barney ab dem 03.07.2025 zu verkaufen. Der geschätzte Gesamtmarktwert beträgt 14.125,86 $. Die Gesamtanzahl der ausstehenden Aktien beträgt 41.977.728, sodass der geplante Verkauf etwa 0,0037 % der ausstehenden Aktien entspricht.

Der Einreicher – in der beigefügten Verkaufshistorie als „10b5-1 Verkaufsplan für Laurent Moll“ und „Laurent Moll“ bezeichnet – hat in den letzten drei Monaten bereits 2.368 Aktien durch mehrere Rule 10b5-1 Transaktionen veräußert und dabei 16.743 $ Bruttoerlöse erzielt. Zusammen mit der neuen Mitteilung belaufen sich die geplanten und kürzlich erfolgten Verkäufe auf insgesamt 3.922 Aktien, was etwa 0,009 % der ausstehenden Aktien entspricht.

Es werden keine Informationen zur Beziehung des Verkäufers zu Arteris, zum Zweck des Verkaufs oder zu wesentlichen, nicht öffentlichen Informationen bereitgestellt, und die Standarderklärung gemäß Rule 144 bestätigt, dass der Verkäufer keine nicht offengelegten nachteiligen Kenntnisse besitzt. Aufgrund der sehr geringen Größe im Verhältnis zum Streubesitz wird die Einreichung voraussichtlich keine wesentlichen Auswirkungen auf den Aktienkurs von AIP haben, aber Investoren könnten den fortgesetzten Insider-Verkaufstrend zur Kenntnis nehmen.

Positive
  • None.
Negative
  • Insider selling activity: Proposed sale of 1,554 shares plus 2,368 shares sold in the prior three months could be viewed cautiously, even if quantitatively immaterial.

Insights

TL;DR Small Form 144 for 1,554 shares; cumulative insider sales remain immaterial to float—signal negligible market impact.

The notice covers a proposed sale worth just over $14 k, following prior 10b5-1 plan sales totaling 2,368 shares in the last quarter. Relative to nearly 42 million shares outstanding, the activity is statistically insignificant (<0.01 %). Such filings are routine liquidity events or plan executions; they rarely influence valuation unless size or frequency is extraordinary. Investors may monitor for accelerating insider disposition, but on current data the filing is neutral for valuation, cash flow, or governance risk.

Arteris, Inc. (NASDAQ: AIP) – Deposito Form 144 rivela che un azionista intende vendere fino a 1.554 azioni ordinarie tramite Morgan Stanley Smith Barney a partire dal 07/03/2025. Il valore di mercato aggregato stimato è di 14.125,86 $. Le azioni totali in circolazione sono 41.977.728, quindi la vendita proposta rappresenta circa lo 0,0037 % delle azioni in circolazione.

Il dichiarante — identificato nella cronologia delle vendite come “Piano di vendita 10b5-1 per Laurent Moll” e “Laurent Moll” — ha già ceduto 2.368 azioni negli ultimi tre mesi tramite diverse transazioni ai sensi della Regola 10b5-1, generando 16.743 $ di proventi lordi. Sommandoli alla nuova comunicazione, le vendite recenti e previste ammontano a 3.922 azioni, ovvero circa lo 0,009 % delle azioni in circolazione.

Non sono fornite informazioni sul rapporto del venditore con Arteris, sullo scopo della vendita o su eventuali informazioni materiali non pubbliche, e la dichiarazione standard della Regola 144 conferma l’assenza di conoscenze sfavorevoli non divulgate da parte del venditore. Data la dimensione minima rispetto al flottante pubblico, il deposito difficilmente influenzerà in modo significativo il prezzo delle azioni AIP, ma gli investitori potrebbero notare la continuazione della tendenza alle vendite da parte degli insider.

Arteris, Inc. (NASDAQ: AIP) – Presentación del Formulario 144 revela que un accionista planea vender hasta 1,554 acciones comunes a través de Morgan Stanley Smith Barney a partir del 07/03/2025. El valor de mercado agregado estimado es de $14,125.86. El total de acciones en circulación es de 41,977,728, por lo que la venta propuesta representa aproximadamente el 0.0037 % de las acciones en circulación.

El declarante — identificado en el historial de ventas adjunto como “Plan de ventas 10b5-1 para Laurent Moll” y “Laurent Moll” — ya ha vendido 2,368 acciones en los últimos tres meses mediante múltiples transacciones bajo la Regla 10b5-1, generando $16,743 en ingresos brutos. Sumando esta nueva notificación, las ventas recientes y contempladas ascienden a 3,922 acciones, o aproximadamente el 0.009 % de las acciones en circulación.

No se proporciona información sobre la relación del vendedor con Arteris, el propósito de la venta ni sobre información material no pública, y la representación estándar de la Regla 144 afirma la ausencia de conocimiento adverso no divulgado por parte del vendedor. Dado el tamaño insignificante en relación con el flotante público, es poco probable que la presentación tenga un impacto material en el precio de las acciones de AIP, pero los inversores pueden notar la tendencia continua de ventas internas.

Arteris, Inc. (NASDAQ: AIP) – Form 144 제출에 따르면 한 주주가 2025년 7월 3일 이후 Morgan Stanley Smith Barney를 통해 최대 1,554 보통주를 매도할 예정입니다. 추정 총 시장 가치는 $14,125.86입니다. 총 발행 주식 수는 41,977,728주로, 이번 매도는 전체 발행 주식의 약 0.0037%에 해당합니다.

신고자—첨부된 매도 내역에서 “Laurent Moll을 위한 10b5-1 매도 계획” 및 “Laurent Moll”로 식별됨—은 지난 3개월 동안 여러 10b5-1 규정에 따른 거래를 통해 이미 2,368주를 처분하여 총 $16,743의 매출을 올렸습니다. 이번 신규 공지와 합산하면 최근 및 예정된 매도는 총 3,922주로, 전체 발행 주식의 약 0.009%에 해당합니다.

판매자의 Arteris와의 관계, 매도 목적, 비공개 중요 정보에 대한 정보는 제공되지 않았으며, 표준 144규정 진술은 판매자가 미공개 불리한 정보를 보유하지 않았음을 확인합니다. 공공 유통 주식 대비 매우 작은 규모이므로 이번 제출이 AIP 주가에 미치는 영향은 크지 않을 것으로 보이나, 투자자들은 내부자 매도 추세가 계속되고 있음을 주목할 수 있습니다.

Arteris, Inc. (NASDAQ : AIP) – Dépôt du formulaire 144 révèle qu'un actionnaire prévoit de vendre jusqu'à 1 554 actions ordinaires via Morgan Stanley Smith Barney à compter du 03/07/2025. La valeur marchande agrégée estimée est de 14 125,86 $. Le nombre total d'actions en circulation est de 41 977 728, de sorte que la vente proposée représente environ 0,0037 % des actions en circulation.

Le déclarant — identifié dans l'historique des ventes joint comme « Plan de vente 10b5-1 pour Laurent Moll » et « Laurent Moll » — a déjà cédé 2 368 actions au cours des trois derniers mois via plusieurs transactions conformément à la règle 10b5-1, générant 16 743 $ de produit brut. En combinant avec cette nouvelle notification, les ventes récentes et envisagées s'élèvent à 3 922 actions, soit environ 0,009 % des actions en circulation.

Aucune information sur la relation du vendeur avec Arteris, l'objet de la vente ou toute information matérielle non publique n'est fournie, et la déclaration standard de la règle 144 confirme l'absence de connaissance défavorable non divulguée par le vendeur. Étant donné la taille négligeable par rapport au flottant public, ce dépôt est peu susceptible d'avoir un impact significatif sur le cours de l'action AIP, mais les investisseurs peuvent noter la poursuite de la tendance des ventes d'initiés.

Arteris, Inc. (NASDAQ: AIP) – Form 144 Einreichung zeigt, dass ein Aktionär beabsichtigt, bis zu 1.554 Stammaktien über Morgan Stanley Smith Barney ab dem 03.07.2025 zu verkaufen. Der geschätzte Gesamtmarktwert beträgt 14.125,86 $. Die Gesamtanzahl der ausstehenden Aktien beträgt 41.977.728, sodass der geplante Verkauf etwa 0,0037 % der ausstehenden Aktien entspricht.

Der Einreicher – in der beigefügten Verkaufshistorie als „10b5-1 Verkaufsplan für Laurent Moll“ und „Laurent Moll“ bezeichnet – hat in den letzten drei Monaten bereits 2.368 Aktien durch mehrere Rule 10b5-1 Transaktionen veräußert und dabei 16.743 $ Bruttoerlöse erzielt. Zusammen mit der neuen Mitteilung belaufen sich die geplanten und kürzlich erfolgten Verkäufe auf insgesamt 3.922 Aktien, was etwa 0,009 % der ausstehenden Aktien entspricht.

Es werden keine Informationen zur Beziehung des Verkäufers zu Arteris, zum Zweck des Verkaufs oder zu wesentlichen, nicht öffentlichen Informationen bereitgestellt, und die Standarderklärung gemäß Rule 144 bestätigt, dass der Verkäufer keine nicht offengelegten nachteiligen Kenntnisse besitzt. Aufgrund der sehr geringen Größe im Verhältnis zum Streubesitz wird die Einreichung voraussichtlich keine wesentlichen Auswirkungen auf den Aktienkurs von AIP haben, aber Investoren könnten den fortgesetzten Insider-Verkaufstrend zur Kenntnis nehmen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Blotz Gerald

(Last) (First) (Middle)
8100 N.E. PARKWAY DRIVE, SUITE 200

(Street)
VANCOUVER WA 98662

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BARRETT BUSINESS SERVICES INC [ BBSI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive VP & COO
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/01/2025 M 6,644 A $0.00 215,740 D
Common Stock 07/01/2025 M 6,896 A $0.00 222,636 D
Common Stock 07/01/2025 M 5,216 A $0.00 227,852 D
Common Stock 07/01/2025 M 3,432 A $0.00 231,284 D
Common Stock 07/01/2025 F 2,653 D $42.65 228,631 D
Common Stock 07/01/2025 F 2,754 D $42.65 225,877 D
Common Stock 07/01/2025 F 2,083 D $42.65 223,794 D
Common Stock 07/01/2025 F 1,371 D $42.65 222,423 D
Common Stock 07/02/2025 S 13,327 D $42.7051(1) 209,096 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (2) 07/01/2025 M 6,644 (3) (3) Common Stock 6,644 $0.00 0.00 D
Restricted Stock Units (2) 07/01/2025 M 6,896 (4) (4) Common Stock 6,896 $0.00 6,892 D
Restricted Stock Units (2) 07/01/2025 M 5,216 (5) (5) Common Stock 5,216 $0.00 10,428 D
Restricted Stock Units (2) 07/01/2025 M 3,432 (6) (6) Common Stock 3,432 $0.00 10,297 D
Restricted Stock Units (2) 07/01/2025 A 511 (7) (7) Common Stock 511 $0.00 511 D
Restricted Stock Units (2) 07/01/2025 A 10,879 (8) (8) Common Stock 10,879 $0.00 10,879 D
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $42.50 to $42.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
2. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.
3. The Restricted Stock Units vest in four annual installments beginning July 1, 2022, and will be settled by delivery of unrestricted shares of common stock on the vesting date.
4. The Restricted Stock Units vest in four annual installments beginning July 1, 2023, and will be settled by delivery of unrestricted shares of common stock on the vesting date.
5. The Restricted Stock Units vest in four annual installments beginning July 1, 2024, and will be settled by delivery of unrestricted shares of common stock on the vesting date.
6. The Restricted Stock Units vest in four annual installments beginning July 1, 2025, and will be settled by delivery of unrestricted shares of common stock on the vesting date.
7. The Restricted Stock Units vest in one installment on July 1, 2030, and will be settled by delivery of unrestricted shares of common stock on the vesting date.
8. The Restricted Stock Units vest in four annual installments beginning July 1, 2026, and will be settled by delivery of unrestricted shares of common stock on the vesting date.
Remarks:
/s/ Anthony Harris, as attorney-in-fact 07/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Arteris (AIP) shares are proposed for sale in the Form 144?

The filing covers 1,554 common shares with an estimated value of $14,125.86.

When is the anticipated sale date for the shares?

The filer lists an approximate sale date of 07 / 03 / 2025.

What percentage of Arteris’s outstanding shares does the sale represent?

Approximately 0.0037 % of the company’s 41,977,728 shares outstanding.

How many Arteris shares has the seller disposed of in the past three months?

Prior Rule 10b5-1 transactions show 2,368 shares sold between April and July 2025.

Which broker will execute the proposed transaction?

The filing names Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.
Barrett Business Svcs Inc

NASDAQ:BBSI

BBSI Rankings

BBSI Latest News

BBSI Latest SEC Filings

BBSI Stock Data

1.10B
24.54M
3.9%
92.35%
1.76%
Staffing & Employment Services
Services-help Supply Services
Link
United States
VANCOUVER